Back

Corporate Information History

2004 onward: Focusing Resources on the Medical Field

Nipro has been focusing its management resources on the medical field, and actively promoting capital investment, alliances and M&A. By integrating the three technologies of medical devices, pharmaceuticals and glass, the company has been making efforts to expand its product lineup and increase its share of the global market. As a comprehensive medical manufacturer, Nipro is making steady progress toward the aim of achieving consolidated sales of 500 billion yen in FY 2020.

2004
April
The company acquired capital in Takeshima Pharmaceutical Corporation. (current Nipro Pharma Corporation Saitama Site)
2005
Full Entry into the Oxygenator Business
April
The company acquired the cardiopulmonary bypass section of Dainippon Ink and Chemicals, and fully entered into the oxygenator business.
June
The company acquired Tohoku Chugai Pharmaceutical Co., Ltd. (current Nipro Pharma Corporation Kagamiishi Plant)to expand its business to solid formulations.
2006
April
The company acquired capital in Zensei Pharmaceutical Industries Co., Ltd.
July
The company transferred the all shares of Nissho Corporation to Hankyu Department Stores, Inc.
August
The company acquired the cardiopulmonary bypass section of Edwards Lifesciences Corporation in the United States to promote the global expansion of the oxygenator business.
October
The company transferred the shares of Nissho Drug Co., Ltd. held by Nipro to Kirindo Co., Ltd., clarifying its policy of concentrating its management resources on its core business (medical devices and pharmaceuticals).
2007
Start of Transdermal Systems
May
The company acquired Saitama Daiichi Pharmaceutical Corporation (current Nipro Pharma Corporation Saitama Site) to expand its business to transdermal systems.
June
The company began integrated production, from the spinning of hollow fiber membranes to the production of dialyzers, at the Odate Plant.
2008
October
The company developed partnerships with ReproCELL Inc. and Cell Science & Technology Institute, Inc. to develop joint business and expand the lineup of culture-medium-related products using ES/iPS cells and somatic stem cells.
2010
Nipro India Corporation PRIVATE LIMITED
February
Nipro India Corporation PRIVATE LIMITED and Nipro Glass India PVT LTD (current Nipro PharmaPackaging India Private Limited)were established in India.
March
The company acquired Home Diagnostics, Inc. (currently named Nipro Diagnostics, Inc.) in the United States as a subsidiary to expand its overseas diabetes-related business.
September
The company acquired capital in Chengdu Pingyuan Nipro Pharmaceutical Packaging Co., Ltd was established to expand its business to medical glass in China.
October
The company acquired capital in Nipro Medical (Hefei) CO., LTD. to expand its business for the purpose of the production of medical devices in China.
November
The company acquired capital in Jilin Nipro Jiaheng Pharmaceutical Packaging Co., Ltd. to expand its business to medical glass in China.
2011
PT. Nipro Indonesia JAYA
January
The company acquired capital in Anyang Nipro Changda Pharmaceutical Packaging Co., Ltd. to expand its business to medical glass in China.
February
PT. Nipro Indonesia JAYA was established in Indonesia.
March
The company acquired JMI Company Ltd. (current Nipro JMI Company Ltd.) to expand its medical business in Bangladesh.
April
The company acquired Tube Glass Containers Ltd. (current Nipro PharmaPackaging India Private Limited) to expand its business to medical glass in India.
July
The company purchased medical glass business in France (current Nipro PharmaPackaging France S.A.S), Belgium (current Nipro PharmaPackaging Belgium N.V.) and the U.S. (current Nipro PharmaPackaging Americas Corp.) from Amcor Limited to expand its medical glass business.
August
The company acquired Nipro Pharma Glass AG, its holding company in Switzerland, to expand its medical glass business in Russia.
2012
January
The company acquired JMI Pharma Ltd. (current Nipro JMI Pharm Ltd.) to launch its pharmaceutical business in Bangladesh.
April
The company purchased MGlas AG (current Nipro PharmaPackaging Germany GmbH) and MG STERILE PRODUCTS AG (current Nipro PharmaPackaging Germany GmbH) to expand its medical glass business in Germany.
2013
Nipro Amtes CO., LTD.
March
The company acquired Goodman CO., LTD. to enhance its cardiovascular business.
June
The company acquired Nchihos Co., Ltd. to expand its business to dispensing pharmacy.
July
The company acquired capital in Infraredx Inc. to expand its cardiovascular business in the U.S.
December
Nipro Amtes CO., LTD. was established for the purpose of the production of medical electronic devices.
2014
Medical Training Facility "Nipro iMEP"
March
The company acquired Cell Science & Technology Institute, Inc. to enhance its cell culture business.
June
Biwako Factory was newly built in Kusatsu Shiga Prefecture as a mother factory for glass business. Otsu Factory was transferred to a new factory.
October
The company opened Nipro iMEP, a medical Training Facility, in Kusatsu, Shiga Prefecture.
2015
April
The medical business of Unitika Ltd. was transferred to the company to enhance test drug business.
October
The company acquired Infraredx, Inc. to enhance cardiovascular business in the U.S.
Nipro PharmaPackaging (Shanghai) Co., Ltd. was established for the purpose of developing medical glass business in China.
2016
January
The company transferred the all shares of Nipro Diagnostics, Inc. to Sinocare, Inc. in China.
June
Nipro System Software Engineering Co., Ltd. was established for the purposes of development, manufacturing and sales of systems such as medical software.
December
The company opened the Regenerative Medicine R&D Center.
2017
January
The company acquired NexMed International Co., Ltd. as a subsidiary to expand its orthopedics business.
March
The company established Nipro Vietnam Company LIMITED in Vietnam to manufacture medical devices.
April
Nipro Pharma Corporation absorbed Nipro Patch Co., Ltd.

Page top